CDMRP Cancer Program Update

The Peer Reviewed Cancer Research Program (PRCRP) of the Congressionally Directed Medical Research Programs (CDMRP) has just announced $130 million in funding opportunities for fiscal year 2022.

Here are the detailed application instructions for the CDMRP awards. Below, we’ve got links for you to download instructions for specific awards.

The CDMRP aim to fund high-risk, high-gain, high-impact projects which other funding agencies may overlook and thus to fill research gaps in critical areas.

What are the Awards?

Each award application must address at least one of the FY22 PRCRP Topic Areas, at least one of the FY22 PRCRP Military Health Focus Areas, and at least one of the FY22 PRCRP Overarching Challenges. Those are listed here.

Below we give a summary of the 2022 PRCRP awards (we’ve got a more detailed overview for you here).

Behavioral Health Science Award

• $1 million over 4 years for research on prevention, survivorship, quality of life, and psychosocial aspects of cancer.
• Preliminary data required.
• Pilot clinical trials allowed.
• Deadlines: Letter of Intent by July 12, Application by August 2.

Career Development Award – Fellow Option

• $400,000 over 3 years for research for early-career investigators to conduct impactful research with mentorship of experienced cancer researchers.
• Preliminary data not required.
• Clinical trials not allowed.
• Deadlines: Letter of Intent by July 12, Application by August 2.

Career Development Award – Virtual Cancer Center Scholar Option

• $800,000 over 4 years to support the addition of new early-career investigators (scholars) to the virtual cancer center focused on fostering the next generation of cancer researchers.
• It’s not required to engage a FY22 PRCRP Overarching Challenges.
• Preliminary data not required.
• Clinical trials not allowed.
• Deadlines: Letter of Intent by July 12, Application by August 2.

Translational Team Science Award

• $2.5 million over 4 years to support translational studies by multiple PIs related to ongoing or completed clinical trials that can lead to a future clinical trial or clinical application in cancer research.
• Preliminary data required.
• Clinical trials allowed.
• Deadlines: Letter of Intent by July 12, Application by August 2.

Convergent Science Cancer Consortium Development Award

• $2.5 million over 4 years to support novel approaches to ending cancer through convergent science research.
• Clinical trials not allowed.
• Deadlines: Letter of Intent by August 17, Application by September 7.

Idea Award

• $400,000 over 2 years to support innovative, untested, high-risk/potentially high-reward concepts,
  theories, paradigms, and/or methods in cancer research.
• Preliminary data not required.
• Clinical trials not allowed.
• Deadlines: Letter of Intent by May 25. Invitation to Submit by
  July 11. Application by September 7.

Impact Award

• $1 million over 3 years to support hypothesis-driven, high impact research projects which have the potential to make a near-term, major impact on one of the FY22 PRCRP Topic Areas.
• Preliminary data required.
• Clinical trials allowed.
• Deadlines: Letter of Intent by May 25. Invitation to Submit by
  July 11. Application by September 7.

How Can FreeMind Help You?

More updates and webinars on non-dilutive funding awards are on the way, so stay tuned.

If you would like to learn how FreeMind can help you apply for these funds and for other non-dilutive grants and contracts, please contact our Director of Marketing Meir Panzer at meir@freemindconsultants.com.